drugset / Trial / NCT06182085
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Phase 2
Completed
304 enrolled
PRInnovation GmbH
Federal Agency for Disruptive Innovation - SPRIN-D · collabJulius Clinical · collabPriavoid · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour. The company PRInnovation is developing a new treatment for Alzheimer's disease, called PRI-002. It is thought that PRI-002 can cut the sticked substances back into small pieces. That would reduce the effects of Alzheimer's disease. In the current study the investigators examine whether PRI-002 is safe and effective in participants with mild cognitive impairment (MCI) or mild dementia due to AD.
Timeline
- Start
- 2024-02-15
- Primary completion
- 2026-04-15
- Completion
- 2026-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PRI-002 | Peptide | — | Oral |